Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Clinical Gastroenterology and Hepatology · 2024-01 · 22 (1) · 102-112.e9
DOI: 10.1016/j.cgh.2023.04.011 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-01. Verfasst von Rohit Loomba und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, San Diego, California. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Co Summit, Bristol-Myers Squibb.
Abstract (Originalsprache)
BACKGROUND & AIMS: Pegbelfermin is a polyethlene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment in patients with nonalcoholic steatohepatitis (NASH) and stage 3 (bridging) fibrosis. METHODS: The FALCON 1 study (NCT03486899) was a multicenter, randomized (1:1:1:1), double-blind, placebo-controlled study. Patients with biopsy-confirmed NASH and stage 3 fibrosis (N = 197) received weekly subcutaneous pegbelfermin (10, 20, or 40 mg) or placebo injections for 48 weeks. The week 24 primary endpoint was a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening; pegbelfermin dose response was assessed using a Cochran-Armitage trend test across proportions (1-sided α = 0.05). Secondary/exploratory endpoints included histological and noninvasive measures of steatosis, fibrosis, and liver injury/inflammation. RESULTS: At week 24, the primary endpoint was met by 14% (placebo) vs 24%-31% (pegbelfermin arms); statistical significance was not reached due to lack of pegbelfermin dose response (P = .134). At weeks 24 and 48, more patients who received pegbelfermin had ≥30% relative reductions in hepatic fat fraction (magnetic resonance imaging-proton density fat fraction) vs placebo, although no differences reached statistical significance. In the pegbelfermin arms, improvements in liver fibrosis (magnetic resonance elastography and N-terminal type III collagen propeptide) and liver injury/inflammation (alanine aminotransferase, aspartate aminotransferase) were observed vs placebo. Adverse events occurred at similar frequencies across arms. No treatment-related serious adverse events were observed. CONCLUSIONS: The FALCON 1 study did not meet its primary endpoint; a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening assessed via biopsy. Pegbelfermin was generally well tolerated during 48 weeks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California San Diego, San Diego, California.
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
- Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri.
- Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia.
- Pinnacle Clinical Research, San Antonio, Texas.
Förderung
- Bristol-Myers Squibb Co Summit
- Bristol-Myers Squibb
Zitieren
APA
Loomba, R., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Harrison, S. A., Lawitz, E. J., Gunn, N., Imajo, K., Ravendhran, N., Akahane, T., Boone, B., Yamaguchi, M., Chatterjee, A., Tirucherai, G. S., Shevell, D. E., Du, S., Charles, E. D., & Abdelmalek, M. F. (2024). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology, 22(1), 102-112.e9. https://doi.org/10.1016/j.cgh.2023.04.011
Vancouver
Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, et al. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology. 2024;22(1):102-112.e9. doi:10.1016/j.cgh.2023.04.011
BibTeX
@article{Loomba2024,
author = {Loomba, Rohit and Sanyal, Arun J and Nakajima, Atsushi and Neuschwander-Tetri, Brent A and Goodman, Zachary D and Harrison, Stephen A and Lawitz, Eric J and Gunn, Nadege and Imajo, Kento and Ravendhran, Natarajan and Akahane, Takemi and Boone, Bradly and Yamaguchi, Masayuki and Chatterjee, Arkendu and Tirucherai, Giridhar S and Shevell, Diane E and Du, Shuyan and Charles, Edgar D and Abdelmalek, Manal F},
title = {Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {1},
pages = {102--112.e9},
doi = {10.1016/j.cgh.2023.04.011}
}
EUVIMED